Thelansis

Giant Axonal Neuropathy (GAN) Market Outlook Thelansis’s “Giant Axonal Neuropathy (GAN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Giant Axonal Neuropathy (GAN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on t...

Giant Axonal Neuropathy (GAN) Market Outlook Thelansis’s “Giant Axonal Neuropathy (GAN) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Giant Axonal Neuropathy (GAN) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Giant Axonal Neuropathy (GAN) Overview Giant Axonal Neuropathy (GAN) is a rare autosomal recessive neurodegenerative disorder impacting both the central and peripheral nervous systems, typically characterized by progressive weakness and ataxia. Alongside these symptoms, individuals experience sensory loss and eventual loss of ambulation, often leading to respiratory failure. The condition stems from an anomaly within...

 Giant Axonal Neuropathy (GAN) is a rare autosomal recessive neurodegenerative disorder impacting both the central and peripheral nervous systems, typically characterized by progressive weakness and ataxia. Alongside these symptoms, individuals experience sensory loss and eventual loss of ambulation, often leading to respiratory failure. The condition stems from an anomaly within the GAN gene, found on chromosome 16 at 16q24.1, responsible for encoding the gigaxonin protein. This abnormal protein results in the swelling of axons, where tiny thread-like deposits of neurofilaments accumulate, creating the appearance of giant axons. Consequently, this leads to degeneration and dysfunctional activity within the peripheral nervous system. Neuropathological investigations have revealed a loss of gigaxonin expression affecting regions such as the cerebellar cortex, brainstem, and posterior columns of the spinal cord. Consequently, this disorder is considered a promising candidate for intr...